StreetAlpha.app
Home › Stocks › IMNM

Immunome Inc. (IMNM)

Healthcare
$15.69
▼ −5.54%
LAST CLOSE · NOV 20

Immunome develops targeted cancer therapies, with a focus on antibody drug conjugates and an investigational treatment for desmoid tumors. It last closed at $15.69 on Nov 20, down 5.54% on the day. The next earnings report for IMNM is expected around Tue, Mar 2, 2027, after the close. For the quarter ended Sep 2026, IMNM reported EPS of -$0.76 on revenue of $0. Over its last 8 reports the stock moved an average of 3.2% the session after earnings. Over the last 12 months IMNM insiders bought $2.3M of stock on the open market and sold $27.5M, according to SEC Form 4 filings.

AI Auto Pilots
Is IMNM in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold IMNM.

Key Stats

Last 12 months
Results
Revenue
$0
−100.0% vs a year ago
Net income
−$282.6M
EPS (diluted)
−$2.63
Free cash flow
−$238.7M
Valuation
Market cap
$1.9B
118.1M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$212.8M
At Sep 30
Shareholder equity
$454.3M
Shares outstanding
118.1M
At Nov 4
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$10K−$10KFY2021FY2022: $5K$5KFY2022FY2023: $14.0M$14.0MFY2023FY2024: $9.0M$9.0MFY2024FY2025: $6.9M$6.9MFY2025

From IMNM's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Next report
Mar 2
Estimated date · After the close
Reported EPS
-$0.76
Quarter ended Sep 2026
Year ago EPS
-$0.65
Same quarter last year
Revenue
$0
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$1.28Dec '24Mar 2025: -$0.52Mar '25Jun 2025: -$0.50Jun '25Sep 2025: -$0.65Sep '25Dec 2025: -$0.75Dec '25Mar 2026: -$0.48Mar '26Jun 2026: -$0.65Jun '26Sep 2026: -$0.76Sep '26Latest -$0.76
Revenue by quarter
Dec 2024: $2.7MDec '24Mar 2025: $2.9MMar '25Jun 2025: $4.0MJun '25Sep 2025: $0Sep '25Dec 2025: $0Dec '25Mar 2026: $0Mar '26Jun 2026: $0Jun '26Sep 2026: $0Sep '26Latest $0
How IMNM moved after its last 8 reports
Average move the session after a report ±3.2%
Nov 9, 2026After the close−3.7%
Aug 11, 2026After the close+6.6%
May 12, 2026After the close−2.2%
Mar 3, 2026After the close+4.5%
Nov 6, 2025After the close−1.7%
Aug 6, 2025After the close−5.6%
May 12, 2025After the close−0.4%
Mar 19, 2025After the close+1.1%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on IMNMStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on IMNM
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on IMNM

Technical Analysis

IMNM · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 17% below its 20 day and 26% below its 50 day average. It is 40% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 32), near oversold. The nearest support is the 52 week low at $15.55, and the nearest resistance the Pivot at $15.99.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 7.9%/day
Key levels
$30.0652 week high+91.6%
$22.50100 day average+43.4%
$21.99200 day average+40.2%
$19.7450 day average+25.8%
$18.44Swing high (Oct 21)+17.5%
$18.3220 day average+16.8%
$16.43Pivot R1+4.7%
$15.99Pivot+1.9%
$15.69Last close
$15.5552 week low−0.9%
$15.25Pivot S1−2.8%
Indicators
RSI (14)31.96Weak, oversold below 30Neutral
MACD-0.82Below its signal lineBearish
Stochastic2.2Near the bottom of its rangeOversold
ADX (14)20.1Weak trend
Williams %R-98.1Oversold below −80, overbought above −20Oversold
CCI (20)-220.3Oversold below −100, overbought above 100Oversold
Rate of change−16.1%Change over 10 sessionsBearish
ATR (14)$1.23Typical daily range, 7.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for IMNM

What happened before

See how IMNM did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow IMNM usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How IMNM has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for IMNMHow many large options trades hit IMNM, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

IMNM Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ●102 buying vs 93 selling
  • ▲Held by funds +1.6 pts
  • ▲Funds holding +7
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding211204+3.4%
In funds' top 10660.0%
Held by funds101.6%100.0%+1.6 pts
New / increased30 / 7230 / 77−4.7%
Reduced / sold out70 / 2362 / 27+4.5%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See IMNM institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

IMNM Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$2.3M8 buys · 3 insiders
Sold$27.5M15 sales · 7 insiders
94% of the selling was under pre-arranged trading plans.
Cluster buy: 2 insiders bought $544K between Mar 10 and Mar 27.
2025-12 bought $1.5M2025-12 sold $8.3M2026-03 bought $544K2026-03 sold $1.3M2026-04 sold $1.6M2026-05 bought $104K2026-06 bought $204K2026-06 sold $2.4M2026-07 sold $8.1M2026-08 sold $5.4M2026-09 sold $334KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Sep 11Jack HigginsChief Scientific OfficerSale plan13,200$25.32$334K
Aug 12Isaac BarchasDirectorSale plan83,464$26.35$2.2M
Aug 7Isaac BarchasDirectorSale plan36,088$26.06$940K
Aug 4Kinney HornChief Business OfficerSale plan90,616$25.09$2.3M
Jul 7Kinney HornChief Business OfficerSale plan1,092$25.00$27K
Jul 7Isaac BarchasDirectorSale plan100,000$24.13$2.4M
Every insider buy and sale for IMNM over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See IMNM insider trades →

From SEC Form 4 filings by IMNM's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IMNM is in one of them and how their past IMNM trades turned out.

IMNM in the AI portfolios
Loading…

IMNM News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered IMNM in an article yet. Here's the latest on the wider market.

IMNM in the news

About Immunome

Immunome is a biotechnology company based in Bothell, Washington, that develops targeted cancer treatments. Its main focus is antibody drug conjugates, a type of therapy that carries cancer fighting drugs to tumor cells, along with other oncology therapies. Its lead candidate, varegacestat, is an investigational oral treatment for desmoid tumors, a rare connective tissue tumor. The company aims to serve cancer patients and the doctors who treat them.

Headquarters
Bothell, WA